MSLN and neoplasm: Our data also identified many novel drug agents that demonstrate anti-tumour activity in vitro and in vivo, and these include the anti-mesothelin immunotoxin SS1 (dsFv)-PE38, the PI3K inhibitor AZD-6482 and the cyclin-dependent kinase inhibitors variolin B, meriolin, alsterpaullone and dinaciclib [206,207,208,209,210,211,212,213].